Read all articles

An exceptional executive opportunity to lead the commercial strategy of HDRS, forging partnerships across healthcare, research and industry to transform access to UK health data and improve patient outcomes.

Appointment recognises Andy’s decade-long contribution to RSA, including team development, scientific expertise and role in building the firm’s West Coast business.

Universal seasonal flu vaccines are entering late-stage trials. Discover the regulatory affairs leaders needed to navigate these international registration programmes.

Using machine learning to identify responsive trial participants reduces patient drop-out and de-risks development timelines. We explore the data-fluent leaders driving this shift.

The clinical validation of next-generation oncology therapeutics brings hope to difficult-to-treat cancers. Sourcing medical directors specialised in solid tumours is critical.

Integrating biomarkers early in drug development improves patient stratification and trial success. Sourcing diagnostic leaders who understand drug-diagnostic co-development is key.